Healthcare Resource Use and Expenditures among Metastatic Breast Cancer Patients Treated with HER2-Targeted Agents

Healthcare Resource Use and Expenditures among Metastatic Breast Cancer Patients Treated with HER2-Targeted Agents

Objective. To compare healthcare utilization (HCU) and costs of women newly diagnosed with metastatic breast cancer (mBC) by receipt of HER2-targeted agents (H2T) and among H2T subgroups. Methods. Adult women newly diagnosed with mBC (index date) during 2008–2012 were followed until enrollment end o...

Full description

Bibliographic Details
Main Authors:	Nicole Meyer, Yanni Hao, Xue Song, Nianwen Shi, William Johnson, Jaqueline Willemann Rogerio, Denise A. Yardley
Format:	Article
Language:	English
Published:	Hindawi Limited 2014-01-01
Series:	International Journal of Breast Cancer
Online Access:	http://dx.doi.org/10.1155/2014/475171

Similar Items

Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab
by: Ran R, et al.
Published: (2020-05-01)

Healthcare Expenditures Channel of Natural Resource Curse: The Case of Gulf Cooperation Council Countries
by: Seyfettin Erdoğan, et al.
Published: (2020-01-01)

Sorafenib is the first targeted agent to treat metastatic kidney cancer
by: V. B. Matveev, et al.
Published: (2015-03-01)

Sorafenib is the first targeted agent to treat metastatic kidney cancer
by: V. B. Matveev, et al.
Published: (2015-03-01)

The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib
by: Natalya V. Mazurina, et al.
Published: (2021-02-01)

Clinical Outcomes, Costs, and Healthcare Resource Utilization in Patients with Metastatic Merkel Cell Carcinoma Treated with Immune Checkpoint Inhibitors vs Chemotherapy
by: Zheng Y, et al.
Published: (2021-03-01)

Risk of neutropenia and healthcare resource utilization in patients with metastatic breast cancer treated with CDK4/6 inhibitors in real-world setting
by: Bergkvist, Anna
Published: (2021)

Efficacy and Safety of Anti-HER2 Agents in Combination With Chemotherapy for Metastatic HER2-Positive Breast Cancer Patient: A Network Meta-Analysis
by: Xiaohui Zhang, et al.
Published: (2021-08-01)

Epidemiology and Healthcare Expenditure of Sepsis in Taiwan
by: Yen-Jung Chen, et al.
Published: (2018)

Baseline Lymphopenia: A Predictor Of Poor Outcomes In HER2 positive Metastatic Breast Cancer Treated With Trastuzumab
by: Che YQ, et al.
Published: (2019-10-01)

CancerCostMod: a model of the healthcare expenditure, patient resource use, and patient co-payment costs for Australian cancer patients
by: Nicole Bates, et al.
Published: (2018-10-01)

Taxanes in the elderly patient with metastatic breast cancer
by: Yardley DA
Published: (2015-09-01)

Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2- Metastatic Breast Cancer
by: Yan Song, et al.
Published: (2015-09-01)

Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2-Metastatic Breast Cancer
by: Yan Song, et al.
Published: (2015-01-01)

Targeting the HER2 Receptor in Metastatic Breast Cancer
by: George Orphanos, et al.
Published: (2012-07-01)

The role of capecitabine and eribulin in the treatment of metastatic HER2-negative metastatic breast cancer
by: I V Kolyadina, et al.
Published: (2018-09-01)

The Role of Corruption and Healthcare Expenditure in Healthcare Systems of the Persian Gulf Region
by: Maryam Asghari
Published: (2016-06-01)

Utilization of Healthcare Services & Healthcare Expenditure Patterns in the Rural Households of Nepal
by: Sachin Pokharel, et al.
Published: (2021-02-01)

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
by: Laura Pizzuti, et al.
Published: (2021-07-01)

Taxanes in the elderly patient with metastatic breast cancer [Corrigendum]
by: Yardley DA
Published: (2019-05-01)

Capecitabine and cisplatin (XP) combination systemic chemotherapy in heavily pre-treated HER2 negative metastatic breast cancer.
by: Jieun Lee, et al.
Published: (2017-01-01)

Socioeconomic differences in healthcare expenditure and utilization in The Netherlands
by: Bette Loef, et al.
Published: (2021-07-01)

Predictors of Healthcare Expenditure: Aging, Disability or Development?
by: Behzad Karami Matin, et al.
Published: (2019-12-01)

Population ageing in Scotland - implications for healthcare expenditure
by: Geue, Claudia
Published: (2012)

Correction to: CancerCostMod: a model of the healthcare expenditure, patient resource use, and patient co-payment costs for Australian cancer patients
by: Nicole Bates, et al.
Published: (2019-01-01)

Dataset used in the economic evaluation trastuzumab-based regimens for HER-2 positive metastatic breast cancer patients in the Taiwanese healthcare setting
by: Vakaramoko Diaby, et al.
Published: (2020-04-01)

Her Majesty's Secret Agents
by: Rogala, Dan
Published: (1978)

Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus
by: Duan F, et al.
Published: (2021-08-01)

HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with <i>RAS</i> Wild Type Metastatic Colorectal Cancer
by: Said A. Khelwatty, et al.
Published: (2021-02-01)

Depth of Response and Early Tumor Shrinkage for Predicting Clinical Outcomes in HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab
by: Che YQ, et al.
Published: (2020-09-01)

Olaparib in the metastatic HER2-negative breast cancer setting
by: L. G. Zhukova, et al.
Published: (2020-12-01)

Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer.
by: Sae-Won Han, et al.
Published: (2012-01-01)

A POPULATION-BASED STUDY OF HEALTHCARE RESOURCE UTILIZATION BY METASTATIC GASTRIC CANCER PATIENTS IN ONTARIO
by: Mahar, ALYSON
Published: (2012)

Dual- versus single-agent HER2 inhibition and incidence of intracranial metastatic disease: a systematic review and meta-analysis
by: Anders Wilder Erickson, et al.
Published: (2021-02-01)

Private expenditures on healthcare: determinants, patterns and progressivity aspects
by: Leah Achdut
Published: (2019-12-01)

The Impacts of Breakthrough Drug Classes on Total Healthcare Expenditures
by: Zeynal Karaca, et al.

Healthcare expenditure and fiscal sustainability: evidence from Switzerland
by: Carsten Colombier, et al.
Published: (2018-09-01)

Assessing the determinants of healthcare expenditures in single-person households
by: Aviad Tur-Sinai, et al.
Published: (2018-10-01)

Inequality of opportunity in healthcare expenditures: evidence from China
by: Yuyang Zhang, et al.
Published: (2020-05-01)

The Effects of Healthcare Expenditure on Economic Growth of Iranian Provinces
by: Mostafa Emadzadeh, et al.
Published: (2012-03-01)

Cannot write session to /tmp/vufind_sessions/sess_f79e5ne60tnnkisnem5at0k0hf